Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-03-18
2008-03-18
Davis, Zinna N. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S336000
Reexamination Certificate
active
07345064
ABSTRACT:
A purpose of the present invention is to provide TNF-α production inhibitors being useful as therapeutic agents for autoimmune diseases such as rheumatoid arthritis. Novel compounds having the structure represented by the general formula [1] or salts thereof according to the present invention have excellent TNF-α production inhibitory activities,wherein A is —(NR4)—, —(CR5R6)— or —O—, B is alkylene or alkenylene, R1, R2, R4, R5and R6are hydrogen, alkyl, alkenyl, adamantyl or the like, R3is aryl or an unsaturated heterocycle, and X is oxygen or sulfer respectively.
REFERENCES:
patent: 3682922 (1972-08-01), Klimstra
patent: 4597902 (1986-07-01), Shanklin, Jr. et al.
patent: 4724235 (1988-02-01), Shanklin, Jr. et al.
patent: 5173506 (1992-12-01), Neustadt et al.
patent: 5190974 (1993-03-01), Clemence et al.
patent: 5356925 (1994-10-01), Neustadt et al.
patent: 5599944 (1997-02-01), Muller et al.
patent: 5674864 (1997-10-01), Clemence et al.
patent: 6033443 (2000-03-01), Aeschlimann
patent: 6034096 (2000-03-01), Bertolini et al.
patent: 6420398 (2002-07-01), Mita et al.
patent: 6492370 (2002-12-01), Mita et al.
patent: 2001/0041725 (2001-11-01), Mita et al.
patent: 2002/0077357 (2002-06-01), Mita et al.
patent: 2002/0198376 (2002-12-01), Mita et al.
patent: 2005/0014800 (2005-01-01), Matsuoka et al.
patent: 0 849 256 (1998-06-01), None
patent: 0 903 434 (1999-03-01), None
patent: 1072591 (2001-01-01), None
patent: 1103543 (2001-05-01), None
patent: 1 457 205 (2004-09-01), None
patent: 9-508115 (1997-08-01), None
patent: WO 92/03410 (1992-03-01), None
patent: WO 92/07567 (1992-05-01), None
patent: WO 95/19957 (1995-07-01), None
patent: WO 95/29909 (1995-11-01), None
patent: WO 97/24328 (1997-07-01), None
patent: WO 97/24355 (1997-07-01), None
patent: WO 97/43251 (1997-11-01), None
patent: WO 98/27069 (1998-06-01), None
patent: WO 99/50238 (1999-10-01), None
patent: WO 00/07985 (2000-02-01), None
patent: WO 00/61552 (2000-10-01), None
Quallich et al, Journal of Organic Chemistry, 1992, vol. 57, pp. 761-764.
Kurose et al., “Asymmetric [2,3]Signmatropic Rearrangement of Chiral Allyic Selenimides”,J. Org. Chem., (1996), vol. 61, pp. 2932-2933, XP001157480.
Braña et al., “Synthesis of 1,2-Di-(4-pyridyl)ethylenediamine and Related Compounds”,J. Heterocycl. Chem., (1987), vol. 24, pp. 369-371, XP009010907.
Mayer et al., “183. Structural Factors Affecting the Basicity of ω-Pyridylalkanols, ω-Pyridylalkanamides and ω-Pyridylalkylamines”,Helvetica Chimica Acta, (1982), vol. 65, Fasc. 6, No. 183, pp. 1868-1884, XP009010908.
A.R. Katritzky, “An Attempt to Simulate the Biogenesis of Stychnine. Part II. Preparation and Transformations of 3-(2-4′-Pyridylacetamidoethyl)indole.”, (1955), pp. 2586-2593, XP009010909.
Böhme et al., “α-Alkylmercapto- and α-Aryolmercapto-alkylisocyanate”,Archiv Pharm. Ber. Dtsch. Pharm. Ges., (1969), vol. 302, No. 5, pp. 335-339, XP009010911.
Shoeb et al., “Studies in Possible Oral Hypoglycaemic Agents: Part V-Synthesis of Carbamoylindoles, Carbamoylisoindolines, 3-Indolylethyl Urea (or Thiourea) & 2- Isoindolinylpropyl Urea (or Thiourea) Derivatives & Their Biological Activity”,J. Chem., (1967), vol. 5, pp. 142-144, XP009010912.
Kunz et al., “Der. 2-(4-Pyridyl)Ethoxycarbonyl-(4-Pyoc)-Rest-Eine Hydrophile . . . ”,Tetrahedron Letters, (1984), vol. 25, No. 33, pp. 3567-3570, XP009010914.
Starnes, S.D.; Rudekevich, D.M.; Rebek, J. Jr., “A Cavitand-Porphyrin Hybrid”, Org. Lett., 2000, vol. 2, No. 14, pp. 1995-1998.
Yamazaki, Clinical Immunology, 27, pp. 1270-1273 (1995) and English language Abstract thereof.
Andreas Eigler et al, Immunology Today, 18, pp. 487-492, (1997).
Ban Masakazu
Enomoto Hiroshi
Horiuchi Masato
Inoue Hiroyuki
Suhara Hiroshi
Davis Zinna N.
Frishauf Holtz Goodman & Chick P.C.
Santen Pharmaceutical Co. Ltd.
LandOfFree
TNF-α production inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with TNF-α production inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TNF-α production inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2809720